NICE approve use of ertugliflozin (Steglatro▼) in treatment of type 2 diabetes
Steglatro▼, for Type 2 diabetes from Merck Sharp and Dohme
- your blood glucose levels can't be managed by diet and exercise alone
- metformin and a DPP‑4 inhibitor are not controlling the diabetes, and
- pioglitazone or a sulfonylurea are not right for you
- alogliptin - brand name Vipidia
- alogliptin with metformin - brand name Vipdomet
- linagliptin - brand name Trajenta
- linagliptin with metformin - brand name Jentadueto
- linagliptin with empagliflozin - brand name Glyxambi
- saxagliptin - brand name Onglyza
- saxagliptin with dapagliflozin - brand name Qtern
- saxagliptin with metformin - brand name Komboglyze
- sitagliptin - brand name Januvia
- sitagliptin with metformin - brand name Janumet
- vildagliptin - brand name Galvus
- vildagliptin with metformin - brand name Eucreas
© NICE  Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes. Technology appraisal guidance [TA583] Published date: 05 June 2019 Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
The information provided by NICE was accurate at the time this article was issued.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.
Sharable Article Link : https://keepmeinformed.eu/Article?articleGuid=cf0afb31-9b9b-4f00-84fd-be170b2caacf